Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

Opinion statement Heart failure (HF) is increasingly recognized as the major complication of
chemotherapy regimens. Despite the development of modern targeted therapies such as …

Anthracyclines, such as doxorubicin, represent one group of chemotherapy drugs with the
most cardiotoxicity. Despite that anthracyclines are capable of treating assorted solid tumors …

Chemotherapy, radiotherapy, targeted therapy, and immunotherapy have brought hope to
cancer patients. With the prolongation of survival of cancer patients and increased clinical …

With the continuous refinement of therapeutic measures, the survival rate of tumor patients
has been improving year by year, while cardiovascular complications related to cancer …

Cancer treatment is associated with various side effects of antitumor agents, which increase
the morbidity and mortality of these patients. Cardiovascular complications are considered to …

Anthracyclines (ANTs) continue to play an irreplaceable role in oncology treatment.
However, the clinical application of ANTs has been limited. In the first place, ANTs can …

Novel therapeutic options have significantly improved survival and long-term outcomes in
many cancer entities. Unfortunately, this improvement in outcome is often accompanied by …

Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin,
which are widely used to treat a variety of malignant tumors, such as breast cancer …

Cardiotoxicity linked to doxorubicin (DOX) is primarily caused by inflammation, oxidative
stress, and apoptosis. The role of tubeimoside I (TBM) in DOX‐induced cardiotoxicity …